by Truveta Research | Aug 23, 2023 | Research, Research Insights
The United States has some of the highest rates of adverse maternal health outcomes compared to other high-income countries (Creanga et al., 2015; Gunja et al., 2022; Taylor et al., 2022). These outcomes have only increased in the last decade (Hoyert, 2023; U.S....
by Truveta staff | Jul 28, 2023 | Research
Scientists from the Institute for Systems Biology (ISB) have published new research in the JMIR Public Health and Surveillance journal. The work explores the National Institute of Health (NIH) recommendation for prophylactic anticoagulant use for pregnant patients...
by Truveta Research | Jul 10, 2023 | Research, Research Insights
We explored the demographic characteristics of patients with type 2 diabetes mellitus, heart failure, and chronic kidney disease who received a prescription for empagliflozin (Jardiance) and/or dapagliflozin (Farxiga), two commonly used SGLT2i drugs. We saw...
by Truveta Research | Jun 6, 2023 | Research, Research Insights
Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023). Physicians have taken to TikTok to promote GLP-1s for weight loss, and celebrities & influencers – such...
by Truveta Research | May 11, 2023 | News, Research
Today Truveta announced a new research letter published in JAMA Network Open using de-identified patient data from Truveta Studio. Published in collaboration with Anupam B. Jena, MD, PhD and Christopher M Worsham, MD, MPH from Harvard University, the new research...
by Truveta Research | May 9, 2023 | Research, Research Insights
This blog is an extension of our poster presented at ISPOR, titled Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin as First-Line Therapy in Type 2 Diabetes. Individuals with type 2 diabetes mellitus (T2DM) have a higher risk of cardiovascular disease...
